CA AB2489

Authorizes the Research Advisory Panel to submit investigational new drug applications to the FDA for clinical trials of Schedule I or II controlled substances (psilocybin, ibogaine) at 20-30 sites statewide for veterans with mental health conditions

Allows expedited state approval of research projects if the FDA fails to timely approve applications, bypassing typical federal approval requirements for controlled substance research

Limits participation to veterans diagnosed with two or more severe or life-threatening mental health conditions who have been deemed ineligible for FDA-approved clinical trials due to comorbidities

Requires applications include independent peer review for scientific merit and institutional review board approval demonstrating compliance with human subjects protections

Sunsets January 1, 2028, and amends existing law to permit controlled substance research approved under "any law" rather than only federal law